Avid Bioservices, Inc. (CDMO): Price and Financial Metrics


Avid Bioservices, Inc. (CDMO)

Today's Latest Price: $8.20 USD

0.05 (0.61%)

Updated Oct 23 6:55pm

Add CDMO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CDMO Stock Summary

  • The price/operating cash flow metric for Avid Bioservices Inc is higher than 95.22% of stocks in our set with a positive cash flow.
  • Of note is the ratio of Avid Bioservices Inc's sales and general administrative expense to its total operating expenses; 83.97% of US stocks have a lower such ratio.
  • As for revenue growth, note that CDMO's revenue has grown 24.12% over the past 12 months; that beats the revenue growth of 81.94% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Avid Bioservices Inc are MC, ROLL, WNS, AAON, and USPH.
  • Visit CDMO's SEC page to see the company's official filings. To visit the company's web site, go to avidbio.com.

CDMO Stock Price Chart Interactive Chart >

Price chart for CDMO

CDMO Price/Volume Stats

Current price $8.20 52-week high $9.10
Prev. close $8.15 52-week low $3.02
Day low $7.96 Volume 139,000
Day high $8.26 Avg. volume 390,380
50-day MA $7.88 Dividend yield N/A
200-day MA $6.52 Market Cap 464.14M

Avid Bioservices, Inc. (CDMO) Company Bio


Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate includes bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company was founded in 1981 and is based in Tustin, California.


CDMO Latest News Stream


Event/Time News Detail
Loading, please wait...

CDMO Latest Social Stream


Loading social stream, please wait...

View Full CDMO Social Stream

Latest CDMO News From Around the Web

Below are the latest news stories about Avid Bioservices Inc that investors may wish to consider to help them evaluate CDMO as an investment opportunity.

Avid Bio +5% after topping FQ1 expectations on expanded margins

Avid Bioservices ([[CDMO]]) Fiscal Q1 2021 results:Revenues: $25.4M (+66.0%).Gross margin for FQ1 was 34%, up significantly compared to 7% for Q1 2020. The increase was primarily due to increased manufacturing revenue from the growth in the number and scale of manufacturing runs, and fees associated with the customer’s unused capacity.Net...

Seeking Alpha | September 2, 2020

Avid Bioservices EPS beats by $0.13, beats on revenue

Avid Bioservices (CDMO): Q1 GAAP EPS of $0.06 beats by $0.13.Revenue of $25.4M (+66.6% Y/Y) beats by $8.9M.Shares +6%."The visibility we currently have into the industry, as well as our customer projections point to continued growth in production demand throughout the year, and it is our priority to be well-positioned...

Seeking Alpha | September 1, 2020

Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript | AlphaStreet

Avid Bioservices, Inc. (NASDAQ: CDMO) Q1 2021 earnings call dated Sep. 01, 2020

AlphaStreet | September 1, 2020

Avid Bioservices, Inc. (CDMO) Q1 2021 Earnings Call Transcript | The Motley Fool

CDMO earnings call for the period ending July 31, 2020.

The Motley Fool | September 1, 2020

U.S. Army Contracting Command Awards Ology Bioservices Contract to Reserve Production Capacity in Support of Operation Warp Speed

ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland. The contract ceiling value is $106.3 million, of which $53.1 million was obligated at the time of award. In this program, Ology Bioservices will manage the reservation of production capacity of approximately 186,840,000 doses of critical vaccines and

Business Wire | August 26, 2020

Read More 'CDMO' Stories Here

CDMO Price Returns

1-mo 9.33%
3-mo 23.68%
6-mo 29.34%
1-year 58.91%
3-year 79.82%
5-year 0.12%
YTD 6.91%
2019 87.07%
2018 5.67%
2017 78.80%
2016 -73.50%
2015 -15.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7826 seconds.